Gland Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/j9izunojwqej6cjeqytwo098.pdf

Key Takeaways


CDMO & Complex Injectables Momentum

Srinivas Sadu: "The CDMO business continues to emerge as a key growth engine for Gland Pharma and remains one of the most important drivers of our long-term strategy."

US & Regulated Markets Performance


Cenexi Turnaround & Profitability Path

Srinivas Sadu: "Cenexi, like earlier said, the growth, the focus is on making it more efficient and make profitable rather than the top line. There will be minimum growth from revenue perspective, but the idea is to make it more profitable."

Capacity Expansion & Capex

Srinivas Sadu: "We actually, we're supposed to take shutdowns a couple of lines, but we're not taking because we don't have capacity to fill if we take shutdown. So that's the situation we are in."

Margins, R&D & Financial Health


Regulatory, Leadership & Strategic Updates

Srinivas Sadu: "One thing is probably not be looking at a loss-making or a very low EBITDA asset. Even if you have to pay a little higher, but we will go with a profitable asset."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growth15% on constant currency basisFY27
Cenexi profitabilityEUR 20 crore at high single-digit EBITDA marginFY27 (guidance confirmed as still on track)
Cenexi profitability returnProfitability to return from Q3 onwardsQ3 FY27
Tax rate normalizationNormalization of overall effective tax rate as Cenexi returns to profitabilityFrom Q3 FY27
ROW market improvementROW market expected to improve in H2H2 FY27
Saudi NUPCO tender13 products participated; tender opening expected this quarterQ3 FY27
Pashamylaram brownfieldThree isolator-based vial lines; ~₹1,000 crore capex; commercial operations commenceFY2030
Vizag SEZ greenfieldBoard approval for additional capex to be soughtNext quarter (Q3 FY27)
Bag line commercializationPost US FDA inspection, de-bottleneck capacityUndated (inspection awaited)
Second in-licensed long-acting injectableClinicals by Gland; manufacturing in China; commercial launch~3 years
Microsphere contractsThree projects; revenue expected post 2029-2030Post 2029-2030
GLP-1 launchesSome launches possible; milestone income and tech transfer fees in FY27Q1/Q2 FY28 (next year)
R&D spend trajectorySlight increase over time; margin levels will be maintainedOngoing

Key Metrics

MetricQ2 FY27
Revenue₹1,833.6 cr, +23% YoY
EBITDA₹480.4 cr, +53% YoY
Adjusted EBITDA₹503 cr, margin 27%
Profit after tax₹290.8 cr, +58% YoY
Gross margin63%, vs 65% in Q1 FY27; H1 FY27 at 64%, flat YoY
R&D spend₹107.7 cr, 6% of revenue, vs ₹77.2 cr in Q1 FY27
CDMO revenue₹822.7 cr, +31% YoY, ~45% of total revenue
Critical injectables revenue₹1,010.9 cr, +18% YoY
US revenue₹1,179.5 cr, +42% YoY
Europe and other regulated markets revenue₹411 cr, +23% YoY
Rest of world revenue₹204.4 cr, impacted by NUPCO tender delay
Cenexi revenueEUR 41 million, vs EUR 40 million in Q2 FY26
Cenexi EBITDAnegative EUR 6 million, due to planned annual summer shutdowns
Cash and cash equivalents₹3,441.2 cr as of Sep 30, 2026
Net cash position₹3,221.6 cr as of Sep 30, 2026
Working capital days158 days, improved driven by inventory optimization
ANDAs filed11 filed, 10 approvals received, 4 products launched in the US
Full-year revenue growth guidance15% on constant currency basis, reiterated
Liquid vials capacity utilization92%, anticipated to reach close to 102% next year
Brownfield capex at Pashamylaram~₹1,000 cr, three isolator-based vial lines, commercial ops from FY2030
Total capex excluding greenfield~₹3,000 cr, adding 300–400 crore units of capacity
Total capex including greenfield~₹5,000 cr over next four years (per an analyst's math, which management did not confirm)